Adapting preparedness outreach to a virtual world.

Over the last two years, agencies have experimented with new systems and tactics to reach as many people as possible with critical preparedness information. This paper describes how COVID-19 forced FEMA Region 10 to adapt its public education and outreach strategy to a fully online space in order to keep the public informed about potential disasters. The paper discusses how the Individual and Community Preparedness team at FEMA Region 10 reaches thousands of people around the world by hosting regular webinars, live events, workshops and training sessions, and publishing a monthly newsletter. The paper also argues that if preparedness and response organisations are to evolve their outreach strategies and messaging plans and extend the reach of their messages, they must continue to adapt and to meet their target audience where they are.

COVID-19 Monoclonal Antibody Administration Linked to Drop in Blood Pressure: A Retrospective Cohort Study.

This study reports on hemodynamic changes observed during monoclonal antibody (mAb) administration for patients with severe acute respiratory distress syndrome-coronavirus-2. Findings from this study may have implications for patient safety. Hemodynamic data from 705 patients who received subcutaneous or intravenous mAb therapy during February 1, 2021-September 30, 2021 in clinics in Arkansas, USA were reviewed. Descriptive statistics and paired t-tests were used to assess blood pressure before and after treatment. Results showed 386 (54.7%) patients experienced a drop in systolic blood pressure (SBP) or diastolic blood pressure (DBP) >5 mmHg. The average drop in SBP was 9.2 mmHg for those patients. Two hundred and eighty-one (39.9%) patients experienced a drop in SBP of >10 mmHg with an average drop in SBP of 12.0 mmHg. The Emergency Use Authorization for mAb does not list hypotension as a contraindication for treatment. Our findings suggest mAb therapy should be administered in an environment where vitals are monitored.

An interesting case of COVID-19 with transient ischemic attack as a delayed neurological complication

COVID-19, the ongoing pandemic is known to affect almost every organ system, however the incidence of TIA is not as well established. So, here, we report a rare case of COVID-19 with transient ischemic attack (TIA) as a delayed complication.

Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.

Monoclonal antibody (mAb) therapy has emerged as one of the mainstay treatment options for SARS-CoV-2. To improve speed of delivery and decrease bedside nursing needs, subcutaneous (SC) delivery of mAbs has been explored as an alternative to standard intravenous (IV) administration. To date, data regarding the effectiveness of SC compared with IV mAb are lacking. This retrospective cohort analysis conducted between April 2021 and August 2021 compared hospitalization rates among patients receiving IV versus SC administration of casirivimab/imdevimab (Regen-COV) at a single institution in Arkansas. Casirivimab/imdevimab was a promising mAb therapy utilized during the height of the Delta variant surge of the SARS-CoV-2 pandemic. Before resistance developed by the Omicron variant, casirivimab/imdevimab was utilized for outpatient treatment of SARS-CoV-2 patients at risk of deterioration. Primary outcomes of this investigation were the 30-day post-treatment rate of hospitalization and intensive care unit (ICU) care during hospitalization. There was no increased risk of hospitalization or ICU care with SC administration compared with IV administration. As SARS-CoV-2 continues to mutate into variants such as Omicron and develop resistance to existing mAbs, these preliminary findings of noninferiority of SC versus IV warrant ongoing investigation into SC administration of other mAbs.

Regional COVID-19 Dynamics: Surrogate Synchrony in Case Infection Rates.

As many jurisdictions consider in-person learning strategies (including at Institutions of Higher Education, IHE), implementing travel restrictions or quarantines, and/or establishing interstate pacts to reduce COVID-19 spread, this study explores the degree to which COVID-19 case infection rates in a group of neighboring, Southern and Midwestern U.S. states (namely, Arkansas and its contiguous neighbors) are patterned in a non-random way known as synchrony. Utilizing surrogate synchrony (SUSY) to estimate the dyadic coupling between the COVID-19 case infection rate processes in this region from March to December 2020, results indicate that significant synchrony is present between Arkansas and three of its neighbors. The highest level of instantaneous synchrony occurs between Arkansas and Tennessee, with the next highest level occurring between Arkansas and Missouri. There is evidence of directionality in the synchrony, indicating that Arkansas case infection rates lead Mississippi while rates in Missouri and Tennessee lead Arkansas. The lagged cross-correlations suggest the greatest synchrony to occur between 3 and 6 days. To explore the effect of IHE reopening on COVID-19, synchrony is compared between pre- and post-reopening windows. Results suggested that, following reopening, there are gains in detectable synchrony and that COVID-19 is in-flowing to Arkansas from all of its neighboring states. Taken together, results suggest that there is spatiality to COVID-19 with neighboring states having case infection rates that are significantly synchronous at a lag time that would be expected based on symptom onset. This synchrony is potentially strengthened by the in-flow and cross-border movement of IHE students.